{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:46:49Z","timestamp":1791960409505,"version":"4.3.4"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.5432","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T18:21:33Z","timestamp":1648837293000},"page":"e225432","source":"Crossref","is-referenced-by-count":27,"title":["Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer"],"prefix":"10.1001","volume":"5","author":[{"given":"Maria E.","family":"Suarez-Almazor","sequence":"first","affiliation":[{"name":"Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xerxes","family":"Pundole","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston"},{"name":"Now with Amgen Inc, Thousand Oaks, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Cabanillas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pacific Hospital of the Valley, Serra Medical Group, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiudong","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda S.","family":"Elting","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Lopez-Olivo","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon H.","family":"Giordano","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"issue":"1","key":"zoi220181r1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.v71.1","article-title":"Cancer statistics, 2021.","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"zoi220181r2","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","article-title":"Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"26","author":"Parker","year":"2015","journal-title":"Ann Oncol"},{"issue":"9327","key":"zoi220181r3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"issue":"15","key":"zoi220181r4","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1200\/JCO.2007.14.9021","article-title":"Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.","volume":"26","author":"Horwitz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi220181r5","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","article-title":"Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma\u2014long-term results of phase III RTOG 85-31.","volume":"61","author":"Pilepich","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"zoi220181r6","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/bonekey.2015.85","article-title":"Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review.","volume":"4","author":"Bienz","year":"2015","journal-title":"Bonekey Rep"},{"issue":"3","key":"zoi220181r7","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.urology.2006.11.002","article-title":"Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer.","volume":"69","author":"Morote","year":"2007","journal-title":"Urology"},{"issue":"2","key":"zoi220181r8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer.","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi220181r9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pds.2258","article-title":"Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States.","volume":"21","author":"Beebe-Dimmer","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"zoi220181r10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074492","article-title":"Mortality following hip fracture in men with prostate cancer.","volume":"8","author":"Van Hemelrijck","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"zoi220181r11","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1007\/s00198-015-3135-9","article-title":"Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.","volume":"26","author":"Wu","year":"2015","journal-title":"Osteoporos Int"},{"issue":"3","key":"zoi220181r12","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.juro.2010.04.068","article-title":"Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men.","volume":"184","author":"Alibhai","year":"2010","journal-title":"J Urol"},{"issue":"6","key":"zoi220181r13","first-page":"4908","article-title":"Fracture risk in androgen deprivation therapy: a Canadian population based analysis.","volume":"16","author":"Lau","year":"2009","journal-title":"Can J Urol"},{"issue":"6 Pt 1","key":"zoi220181r14","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1097\/01.ju.0000141515.67372.e5","article-title":"The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate.","volume":"172","author":"Bae","year":"2004","journal-title":"J Urol"},{"issue":"5","key":"zoi220181r15","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.","volume":"100","author":"Diamond","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"zoi220181r16","first-page":"2962","article-title":"GU radiation oncologists consensus on bone loss from androgen deprivation.","volume":"13","author":"Duncan","year":"2006","journal-title":"Can J Urol"},{"issue":"5","key":"zoi220181r17","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1016\/S0022-5347(05)65060-4","article-title":"Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.","volume":"167","author":"Ross","year":"2002","journal-title":"J Urol"},{"issue":"3","key":"zoi220181r18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/cncr.11149","article-title":"Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.","volume":"97","author":"Smith","year":"2003","journal-title":"Cancer"},{"issue":"31","key":"zoi220181r19","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1200\/JCO.19.01696","article-title":"Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline.","volume":"37","author":"Shapiro","year":"2019","journal-title":"J Clin Oncol"},{"key":"zoi220181r20","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2013.0215","article-title":"NCCN Task Force report: bone health in cancer care.","volume":"11","author":"Gralow","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"zoi220181r21","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1210\/jc.2011-3045","article-title":"Osteoporosis in men: an Endocrine Society clinical practice guideline.","volume":"97","author":"Watts","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"zoi220181r22","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00520-013-2008-z","article-title":"Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy.","volume":"22","author":"Suarez-Almazor","year":"2014","journal-title":"Support Care Cancer"},{"issue":"4","key":"zoi220181r23","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/cncr.27830","article-title":"Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy.","volume":"119","author":"Morgans","year":"2013","journal-title":"Cancer"},{"issue":"11","key":"zoi220181r24","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1007\/s11606-013-2477-2","article-title":"Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.","volume":"28","author":"Shahinian","year":"2013","journal-title":"J Gen Intern Med"},{"issue":"4","key":"zoi220181r25","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/bju.14075","article-title":"The implications of baseline bone-health assessment at initiation of androgen-deprivation therapy for prostate cancer.","volume":"121","author":"Kirk","year":"2018","journal-title":"BJU Int"},{"issue":"3","key":"zoi220181r26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jama.2011.2022","article-title":"Screening for osteoporosis in men receiving androgen deprivation therapy.","volume":"307","author":"Alibhai","year":"2012","journal-title":"JAMA"},{"issue":"10","key":"zoi220181r27","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.6004\/jnccn.2020.7576","article-title":"Contemporary population-based analysis of bone mineral density testing in men initiating androgen deprivation therapy for prostate cancer.","volume":"18","author":"Hu","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"zoi220181r28","article-title":"Updated overview of the SEER-Medicare data: enhanced content and applications.","author":"Enewold"},{"issue":"5","key":"zoi220181r30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"zoi220181r31","author":"Klabunde","year":"2000"},{"issue":"5","key":"zoi220181r32","doi-asserted-by":"crossref","first-page":"813","DOI":"10.6004\/jnccn.2014.0196","article-title":"NCCN Bone Health Task Force: key recommendations.","volume":"12","author":"Farooki","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"zoi220181r33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1177\/1078155211402105","article-title":"Bone health management in prostate cancer patients receiving androgen deprivation therapy.","volume":"18","author":"Dhanapal","year":"2012","journal-title":"J Oncol Pharm Pract"},{"key":"zoi220181r34","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/958596","article-title":"The current practice of screening, prevention, and treatment of androgen-deprivation\u2013therapy induced osteoporosis in patients with prostate cancer.","volume":"2012","author":"Al-Shamsi","year":"2012","journal-title":"J Oncol"},{"key":"zoi220181r35","author":"El Badri","year":"2019"},{"issue":"5","key":"zoi220181r36","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.euo.2018.11.001","article-title":"Preventing osteoporosis in men taking androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis.","volume":"2","author":"Joseph","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"zoi220181r37","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/jbmr.v36.5","article-title":"Bone mineral density at the time of initiating aromatase inhibitor therapy is associated with decreased fractures in women with breast cancer.","volume":"36","author":"Lu","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"4","key":"zoi220181r38","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00198-009-0984-0","article-title":"Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX.","volume":"21","author":"Adler","year":"2010","journal-title":"Osteoporos Int"},{"issue":"3","key":"zoi220181r39","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0022-5347(05)64561-2","article-title":"Skeletal fractures negatively correlate with overall survival in men with prostate cancer.","volume":"168","author":"Oefelein","year":"2002","journal-title":"J Urol"},{"issue":"31","key":"zoi220181r40","doi-asserted-by":"publisher","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","article-title":"Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi220181r41","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00198-009-0920-3","article-title":"Excess mortality following hip fracture: a systematic epidemiological review.","volume":"20","author":"Abrahamsen","year":"2009","journal-title":"Osteoporos Int"},{"issue":"12","key":"zoi220181r42","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures.","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos Int"},{"key":"zoi220181r29","unstructured":"Comparative Effectiveness Research on Cancer in Texas. Welcome to Comparative Effectiveness Research on Cancer in Texas. The University of Texas Medical Branch at Galveston; 2022. Accessed February 28, 2022. https:\/\/www.utmb.edu\/scoa\/research\/supported-research-programs\/comparative-effectiveness-research-on-cancer-in-texas\/home"},{"key":"zoi220181r43","unstructured":"American Cancer Society. Cancer facts & figures 2020. 2020. American Cancer Society; 2021. Accessed February 28, 2022. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2020.html"},{"key":"zoi220181r44","unstructured":"Howlader? N, Noone? AM, Krapcho? M, . SEER cancer statistics review (CSR) 1975-2016. National Cancer Institute; April 2019. Accessed February 28, 2022. https:\/\/seer.cancer.gov\/archive\/csr\/1975_2016"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2790600\/suarezalmazor_2022_oi_220181_1648050780.55819.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T18:22:12Z","timestamp":1648837332000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2790600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.5432","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]}}}